Novel Med Shows Early, Lasting Gains in Resistant Epilepsy

Author profile image Aggregator
0 comments
A novel ASM significantly reduced focal seizures within the first week of treatment, with sustained benefit over 12 weeks in adults with drug-resistant epilepsy.
Medscape Medical News

Source: Medscape Neurology Published 20 Nov 2026 Imported 20 Nov 2026 Relevancy: Not reviewed

Read the article